Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.358
-$0.0541-13.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.35M | -11.21M | -13.43M | -17.51M | -19.70M |
| Total Depreciation and Amortization | 4.00K | 6.00K | 13.00K | 19.00K | 25.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.04M | 555.00K | 770.00K | 1.04M | 1.22M |
| Change in Net Operating Assets | -4.45M | 2.66M | 2.10M | 4.93M | 8.72M |
| Cash from Operations | -10.75M | -7.99M | -10.54M | -11.51M | -9.73M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.72M | 7.82M | 7.26M | 7.26M | 1.05M |
| Repurchase of Common Stock | -1.00K | -1.00K | -1.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -50.00K | -100.00K | -151.00K |
| Other Financing Activities | -169.00K | 0.00 | 0.00 | 0.00 | -79.00K |
| Cash from Financing | 11.55M | 7.82M | 7.21M | 7.16M | 819.00K |
| Foreign Exchange rate Adjustments | -141.00K | -73.00K | 374.00K | 190.00K | 278.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 652.00K | -241.00K | -2.96M | -4.16M | -8.64M |